On the public citation graph

Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors

0 signed · 47 inferred · view as graph

Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.

Is this your work? Sign in with ORCID and put your name on the claims that are yours.
Claim with ORCID
Reference health. See whether every reference in this work resolves to a known work and none has been retracted — and get a dated CiteStamped badge you can embed.
See reference health

What this work says

Outgoing claims: the papers this work cites, builds on, or argues with.

inferredcites →https://doi.org/10.1002/rth2.12248openalex-snapshot
Low‐dose immune tolerance induction for children with hemophilia A with poor‐risk high‐titer inhibitors: A pilot study in China
inferredcites →https://doi.org/10.1002/rth2.12562openalex-snapshot
Low‐dose immune tolerance induction alone or with immunosuppressants according to prognostic risk factors in Chinese children with hemophilia A inhibitors
inferredcites →https://doi.org/10.1016/j.transci.2019.08.008openalex-snapshot
Hemophilia A with inhibitor: Immune tolerance induction (ITI) in the mirror of time
inferredcites →https://doi.org/10.1046/j.1365-2516.2002.00626.xopenalex-snapshot
Inhibitors: resolving diagnostic and therapeutic dilemmas
inferredcites →https://doi.org/10.1055/s-0038-1653759openalex-snapshot
The Nijmegen Modification of the Bethesda Assay for Factor VIII:C Inhibitors: Improved Specificity and Reliability
inferredcites →https://doi.org/10.1055/s-0040-1713097openalex-snapshot
ITI Treatment is not First-Choice Treatment in Children with Hemophilia A and Low-Responding Inhibitors: Evidence from a PedNet Study
inferredcites →https://doi.org/10.1097/mph.0000000000001391openalex-snapshot
Low-dose Immune Tolerance Induction in Hemophilia: A Single-Center Experience
inferredcites →https://doi.org/10.1111/bjh.12091openalex-snapshot
Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition)
inferredcites →https://doi.org/10.1111/hae.12051openalex-snapshot
The immune tolerance induction ( ITI ) dose debate: does the International ITI Study provide a clearer picture?
inferredcites →https://doi.org/10.1111/hae.12052openalex-snapshot
Management of patients with long‐term inhibitors: is immune tolerance an underestimated life‐long solution?
inferredcites →https://doi.org/10.1111/hae.12102openalex-snapshot
Immune tolerance induction in haemophilia A patients with inhibitors by treatment with recombinant factor VIII: a retrospective non‐interventional study
inferredcites →https://doi.org/10.1111/hae.12774openalex-snapshot
First prospective report on immune tolerance in poor risk haemophilia A inhibitor patients with a single factor VIII/von Willebrand factor concentrate in an observational immune tolerance induction study
inferredcites →https://doi.org/10.1111/hae.12986openalex-snapshot
Long‐term outcome of haemophilia A patients after successful immune tolerance induction therapy using a single plasma‐derived FVIII/VWF product: the long‐term ITI study
inferredcites →https://doi.org/10.1111/hae.13264openalex-snapshot
First‐line immune tolerance induction for children with severe haemophilia A: A protocol from the UK Haemophilia Centre Doctors' Organisation Inhibitor and Paediatric Working Parties
inferredcites →https://doi.org/10.1111/hae.13294openalex-snapshot
Estimating the potential cost of a high dose immune tolerance induction ( ITI ) therapy relative to the cost of a combined therapy of a low dose ITI therapy with bypassing agent prophylaxis
inferredcites →https://doi.org/10.1111/hae.13762openalex-snapshot
The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab
inferredcites →https://doi.org/10.1111/hae.14046openalex-snapshot
WFH Guidelines for the Management of Hemophilia, 3rd edition
inferredcites →https://doi.org/10.1111/j.1365-2141.2010.08263.xopenalex-snapshot
Optimizing management of immune tolerance induction in patients with severe haemophilia A and inhibitors: towards evidence‐based approaches
inferredcites →https://doi.org/10.1111/j.1365-2516.2005.01170.xopenalex-snapshot
Rituximab for congenital haemophiliacs with inhibitors: a Canadian experience
inferredcites →https://doi.org/10.1111/j.1365-2516.2007.01497.xopenalex-snapshot
International workshop on immune tolerance induction: consensus recommendations1
inferredcites →https://doi.org/10.1111/j.1365-2516.2007.01621.xopenalex-snapshot
Low‐dose immune tolerance induction for paediatric haemophilia patients with factor VIII inhibitors
inferredcites →https://doi.org/10.1111/j.1365-2516.2009.02191.xopenalex-snapshot
Limited blood sampling for pharmacokinetic dose tailoring of FVIII in the prophylactic treatment of haemophilia A
inferredcites →https://doi.org/10.1111/j.1365-2516.2010.02225.xopenalex-snapshot
Successful low dose immune tolerance induction in severe haemophilia A with inhibitors below 40 Bethesda Units
inferredcites →https://doi.org/10.1111/j.1423-0410.1999.tb00015.xopenalex-snapshot
Induction of Immune Tolerance in Haemophilia A Inhibitor Patients by the ‘Bonn Protocol‘: Predictive Parameter for Therapy Duration and Outcome
inferredcites →https://doi.org/10.1111/j.1538-7836.2009.03332.xopenalex-snapshot
Rituximab and immune tolerance in severe hemophilia A: a consecutive national cohort
inferredcites →https://doi.org/10.1160/th15-08-0692openalex-snapshot
Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors
inferredcites →https://doi.org/10.1182/blood-2011-08-369132openalex-snapshot
The principal results of the International Immune Tolerance Study: a randomized dose comparison
inferredcites →https://doi.org/10.1182/blood-2011-09-379453openalex-snapshot
F8 gene mutation type and inhibitor development in patients with severe hemophilia A: systematic review and meta-analysis
inferredcites →https://doi.org/10.1182/bloodadvances.2017009209openalex-snapshot
The impact of von Willebrand factor on factor VIII memory immune responses

What points at this work

Incoming claims: where this work appears in other papers’ reference lists and arguments.

inferred← citeshttps://doi.org/10.2139/ssrn.4789895openalex-extracted
Maternal Microchimerism Promotes Tolerance Induction Toward Factor VIII in Severe Haemophilia a Children with Inhibitors
inferred← citeshttps://doi.org/10.1002/ped4.12429openalex-snapshot
Low‐dose immune tolerance induction for severe hemophilia A inhibitor patients: Immunosuppressants are generally not necessary for inhibitor‐titer below 200 BU/mL
inferred← citeshttps://doi.org/10.1002/rth2.12824openalex-snapshot
Low‐dose immune tolerance induction in children with severe hemophilia A with high‐titer inhibitors: Type of factor 8 mutation and outcomes
inferred← citeshttps://doi.org/10.1016/j.jtha.2025.04.015openalex-snapshot
Outcomes of immune tolerance induction with rituximab to eradicate high-titer inhibitor of hemophilia A: depicted by exponential decay model and the gene expression profile of different outcomes by RNA-sequencing
inferred← citeshttps://doi.org/10.1016/j.rpth.2024.102639openalex-snapshot
Intermediate-dose immune tolerance induction outperforms with faster success, less bleeding, and no added cost in comparison with low dose: a multicenter randomized clinical trial
inferred← citeshttps://doi.org/10.1016/j.rpth.2026.103425openalex-snapshot
Emicizumab prophylaxis vs immune tolerance induction in children with severe hemophilia A and inhibitors: a retrospective comparison of bleeding control, quality of life, and cost
inferred← citeshttps://doi.org/10.1016/j.thromres.2023.01.025openalex-snapshot
The efficacy of the rituximab-containing rescue-regimen for severe hemophilia A inhibitor children who relapsed following successful immune tolerance induction with rituximab in China
inferred← citeshttps://doi.org/10.1016/j.thromres.2023.02.011openalex-snapshot
The efficacy of sequential MMF-rescue-regimen to eradicate inhibitors for refractory severe hemophilia A inhibitor children in China
inferred← citeshttps://doi.org/10.1016/j.thromres.2023.02.016openalex-snapshot
Low-dose immune tolerance induction therapy in severe hemophilia a children in China: Starting earlier resulted in better inhibitor eradication outcomes
inferred← citeshttps://doi.org/10.1021/acsptsci.4c00560openalex-snapshot
Advances in Development of Drug Treatment for Hemophilia with Inhibitors
inferred← citeshttps://doi.org/10.1080/16078454.2023.2250601openalex-snapshot
Application of peripherally inserted central catheter in immune tolerance induction treatment of children with hemophilia A and accompanying inhibitors in China
inferred← citeshttps://doi.org/10.1080/16078454.2025.2564511openalex-snapshot
The effectiveness and safety of various treatments for hemophilia in China: a literature review and evidence mapping
inferred← citeshttps://doi.org/10.1080/17474086.2023.2293092openalex-snapshot
National strategic advocacy to manage patients with inherited bleeding disorders in low and lower-middle income countries
inferred← citeshttps://doi.org/10.1111/hae.14577openalex-snapshot
Eradication of FIX inhibitor in haemophilia B children using low‐dose immune tolerance induction with rituximab‐based immunosuppressive agent(s) in China
inferred← citeshttps://doi.org/10.3389/fimmu.2026.1829007openalex-snapshot
Outcomes of low-dose immune tolerance induction with single-dose rituximab in severe hemophilia A: a single-center retrospective experience
inferred← citeshttps://doi.org/10.3760/cma.j.issn.0253-2727.2023.11.001openalex-snapshot
[Chinese guidelines on the diagnosis and management of hemophilia with inhibitors (2023)].
inferred← citeshttps://doi.org/10.70187/recisatec.v4i2.371openalex-snapshot
PROCESO DE ATENCIÓN DE ENFERMERÍA EN UN PACIENTE CON HEMOFILIA TIPO A - REPORTE DE CASO CLÍNICO
showing the first 17 of 18 · page through all 18
Editorial review for independent work. ICSAC — the Institute for Complexity Science and Advanced Computing — runs a structured editorial panel for researchers publishing outside journals, and publishes on CiteStamp rails. Submission is free and goes through ORCID: icsacinstitute.org/submit.